GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
GERON CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.20+0.03 (+2.56%)
Close on Oct 19, 2026
- Market cap
- $804.84K
- P/E (TTM)
- –
- Dividend yield
- –
GERON CORP revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product revenue | $257.72M | $243.15M | $223.11M | $219.25M | $191.71M | $134.73M | $89.42M | – | – | – | – | 55.7% | +34.4% |
| Product revenue, net | $204.42M | $195.96M | $183.62M | $183.12M | $164.16M | $115.93M | $76.50M | – | – | – | – | 44.2% | +24.5% |
| Royalties | $135.00K | $157.00K | $258.00K | $287.00K | $289.00K | $362.00K | $499.00K | $491.00K | $593.00K | $520.00K | $237.00K | 0.0% | -53.3% |
| Government rebates | -$5.71M | -$4.20M | -$2.60M | – | – | – | – | – | – | – | – | -1.2% | – |
By region
From the segment and revenue-disaggregation notes of Geron's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.